ClinicalTrials.gg
RecruitingNCT07444450STELLAR-2Updated Oct 15, 2026

A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

A Phase 3 interventional study of Salanersen and Sham Procedure in Muscular Atrophy, Spinal, sponsored by Biogen. Recruiting at 1 site in United States. Open to participants aged 0 Days to 7 Months. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
0 Days to 7 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Muscular Atrophy, Spinal by Biogen — 5 open to participants now, 10 under way, 4 of them phase 3. Muscular Atrophy, Spinal · Biogen.

Planned enrollment
14th of 21
42 · median 47
Started
2026
with 2 others
Phase 3
9 of 27
3 open now
Registered
26th of 27
by date

Among the 27 studies in Muscular Atrophy, Spinal by Biogen, this one is the 14th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 in phase 3, and was the 26th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 72 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

5 of the 27 studies in Muscular Atrophy, Spinal by Biogen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 57 Muscular Atrophy, Spinal studies recruiting now, 28 (49%) set no upper age limit and 26 (46%) stop at 75 or younger; 45 take children under 18; 11 take healthy volunteers.

This study: 0 Days to 7 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Atrophy, Spinal by Biogen, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the safety and effects of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have already been treated with onasemnogene abeparvovec (OA) after being diagnosed with SMA.

Most people with SMA have changes in a gene called survival motor neuron 1, also known as SMN1. These changes lower the amount of SMN protein in their bodies. Without enough of this protein, motor neurons and muscles cannot work properly. A similar gene called SMN2 can help replace some of the lost SMN protein in the body. Salanersen works by helping the SMN2 gene to make more SMN protein.

OA works by replacing the missing or abnormal SMN1 gene. Sometimes, OA treatment may not work as well as expected. As a result, researchers are exploring whether giving another drug after OA could lead to better outcomes for people with SMA.

In this study, participants will have 2 SMN2 copies. The higher the copy number, the less severe the participant's SMA is. They will also have received treatment with OA by the time they were 42 days old and before showing any symptoms of SMA.

The main goal of the study is to learn more about the safety of giving salanersen to babies after OA treatment. Researchers will also learn more about whether salanersen can help make SMA symptoms less serious.

The main question researchers want to answer in this study is:

  • How many participants have adverse events and serious adverse events after treatment?

Researchers will also learn more about:

  • The effects on participants' motor symptoms and how many new movement milestones participants achieve.
  • How many participants stay free of SMA symptoms.
  • How much neurofilament protein is found in the blood after treatment.
  • How much salanersen gets into the fluid surrounding the brain and spinal cord.
  • How much salanersen gets into the blood. Researchers will use different tests to learn if motor symptoms are changing, including the World Health Organization (WHO) motor milestones and Hammersmith Infant Neurological Examination (HINE) Section 2 motor milestones.

The study will be done in 2 parts. Part A will last 1 year while Part B will last up to 4 years.

The study will be done as follows:

  • First, participants will be screened to check if they can join the study. The screening period will be up to 6 months. Participants must have received OA treatment before the age of 42 days and started screening within 6 months of the OA dose.
  • Participants will be assigned to 1 of 2 treatment groups by chance. This is a "double blind" study which means neither the participants, study doctor, nor site staff will know which treatment group the participants are assigned to.
  • In this study, salanersen will be given as an intrathecal injection, which is an injection into the fluid surrounding the spine. This is done by a procedure called a lumbar puncture (LP) which involves inserting a needle into the lower back into the space around the spinal cord.
  • During Part A, one group will receive 80 milligrams (mg) of salanersen while another group receives a sham (fake) procedure. This means that a small needle prick will be done, but no injection will be given.
  • For each participant, the first visit of Part A will be 6 months after they receive OA treatment.
  • Part A will have up to 6 clinic visits and 2 phone calls and last up to 1 year.
  • During Part B, both groups of participants will receive 80 mg of salanersen once a year.
  • Part B will have up to 12 clinic visits and 14 phone calls and last up to 4 years.
  • In total, participants will be in the study for up to 5 and a half years.
Read the detailed description

The primary objective of the study is to evaluate the safety and tolerability of adding salanersen 6 months after OA in participants with genetically diagnosed SMA who received presymptomatic treatment with OA.

The secondary objectives are to evaluate the efficacy and effect on biomarkers of salanersen after OA, and to evaluate the pharmacokinetics (PK) of salanersen in participants with genetically diagnosed SMA who have received presymptomatic treatment with OA.

03

Conditions studied

  • Muscular Atrophy, Spinal
04

Who can participate

Ages eligible
0 Days to 7 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Genetic documentation of 5q spinal muscular atrophy (SMA) homozygous gene deletion or mutation or compound heterozygous mutation.
  • 2 copies of the survival motor neuron 2 (SMN2) gene.
  • Onasemnogene Abeparvovec (OA) dose given at ≤ 42 days of age and screening initiated less than 6 months from OA dosing.
  • OA dose given while participant was presymptomatic, per Investigator attestation. For this study, presymptomatic is defined as follows:

    • No clinical signs or symptoms at the time of OA dosing that are, in the opinion of the Investigator, strongly suggestive of SMA.
    • No absence of tendon reflexes (i.e., absence of all of biceps, knee and ankle tendons) at the time of OA dosing (e.g., Hammersmith Infant Neurological Examination (HINE) Section 1 or equivalent).
    • If Compound Muscle Action Potential (CMAP) data is available at the time of dosing, ulnar CMAP amplitude ≥ 2 millivolt (mV).

Key Exclusion Criteria:

  • Any unresolved post-OA laboratory abnormalities defined as follows:

    • (ALT) or aspartate aminotransferase (AST) must be less than 2 × (ULN) while not receiving within 30 days prior to dosing with salanersen or sham procedure (repeat testing may be performed if necessary).
    • Evidence of thrombocytopenia, indicated by the count being lower than the normal range for the laboratory.
    • Evidence of elevated troponin-I levels, identified as elevated post-OA, and has not returned to the normal range.
  • Confirmed demonstration of interval, using Fridericia's correction method, of > 450 milliseconds (ms).
  • Other than OA, any prior treatment with an approved SMA disease modifying therapy (e.g. nusinersen and/or risdiplam), a myostatin inhibitor therapy, or an drug given for the treatment of SMA.
  • Steroid treatment administered for the purpose of treating complications following OA within 14 days prior to dosing with salanersen or sham procedure on Day 1.

Note: Other protocol-defined inclusion/exclusion criteria will apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Salanersen

    Participants will receive a single dose of salanersen, 80 milligrams (mg) administered intrathecally on Day 1 in Part A. In Part B, participants will continue to receive four additional intrathecal doses of salanersen, 80 mg administered on Days 365, 730, 1095, and 1460.

    Drug: Salanersen

  • Sham comparator
    Sham Procedure

    Participants will undergo a sham procedure on Day 1 in Part A. In Part B, participants will receive four intrathecal doses of salanersen, 80 mg administered on Days 365, 730, 1095, and 1460.

    Drug: Salanersen · Procedure: Sham Procedure

Interventions

  • Administered intrathecally

    Also known as: BIIB115

  • ProcedureSham Procedure

    A sham lumbar puncture is a skin-only needle prick at the usual lumbar puncture site. The needle does not enter the spinal canal.

06

What researchers measure

Primary outcomes

  1. Parts A: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Part A: Up to Day 365

Secondary outcomes

  1. Part B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Part B: Up to Day 1825

  2. Parts A and B: Change From Baseline in Plasma Levels of Neurofilament Light Chain (NfL)

    Blood will be collected to characterize changes in plasma NfL following treatment with salanersen. NfL is a protein released from damaged neurons and is a biomarker of neurodegeneration.

    Time frame: Part A: At Days 180 and 365; Part B: Up to Day 1825

  3. Parts A and B: Change from Baseline in Compound Muscle Action Potential (CMAP) Amplitudes

    CMAP is a well-validated method for tracking disease progression in neuromuscular disorders such as SMA and amyotrophic lateral sclerosis and has been proposed as a potential biomarker of a therapeutic effect in SMA. CMAPs will be performed for the following nerve-muscle pairs: ulnar-abductor digiti minimi and peroneal-tibialis anterior.

    Time frame: Part A: At Day 365 and Part B: Up to Day 1825

  4. Parts A and B: Percentage of Participants Attaining World Health Organization (WHO) Motor Milestones

    The WHO motor milestones will include six key developmental milestones: sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone, and walking alone.

    Time frame: Part A: At Day 365 and Part B: Up to Day 1825

  5. Parts A and B: Percentage of Participants Attaining Hammersmith Infant Neurological Examination Section 2 (HINE-2) Motor Milestones

    Section 2 of the HINE is used to assess motor milestones and includes 8 motor milestone categories: voluntary grasp (0 to 3), ability to kick in supine position (0 to 4), head control (0 to 2), rolling (0 to 3), sitting (0 to 4), crawling (0 to 4), standing (0 to 3), and walking (0 to 3). Total HINE-2 score is the sum of points from each item and can range from 0 to 26, with higher scores depicting a better level of ability.

    Time frame: Part A: At Day 365 and Part B: Up to Day 1825

  6. Parts A and B: Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale

    The CHOP INTEND test is designed to evaluate the motor skills of participants with significant motor weakness. It includes 16 items (capturing neck, trunk, and proximal and distal limb strength) structured to move from easiest to hardest with the grading including gravity eliminated (lower scores) to antigravity movements (higher scores). All item scores range from 0-4. The total score ranges from 0-64, with higher scores depicting better motor function.

    Time frame: Part A: At Day 365 and Part B: Up to Day 1825

  7. Parts A and B: Percentage of Participants who Remain Free of Clinically Manifested Spinal Muscular Atrophy (SMA)

    Time frame: Part A: At Day 365 and Part B: At Day 545

  8. Part B: Percentage of Participants who Develop Spinal Muscular Atrophy (SMA) Subtypes (Non-Sitters, Sitters and Walkers) as Assessed by the Investigator

    Time frame: Part B: Up to Day 1825

  9. Part B: Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score

    The HFMSE is a tool used to assess motor function in individuals with SMA. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66, with higher scores depicting better ability to perform activities.

    Time frame: Part B: Up to Day 1825

  10. Part B: Revised Upper Limb Module (RULM) Total Score

    The RULM is developed to assess upper limb functional abilities of participants with SMA. This test consists of a total of 20 upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function.

    Time frame: Part B: Up to Day 1825

  11. Parts A and B: Time to Death (Overall Survival)

    Time frame: Part A: Up to Day 365 and Part B: Up to Day 1825

  12. Parts A and B: Time to Death or Permanent Ventilation

    Permanent ventilation is defined as tracheostomy or ≥16 hours ventilation/day continuously for \>21 days in the absence of an acute reversible event.

    Time frame: Part A: Up to Day 365 and Part B: Up to Day 1825

  13. Parts A and B: Concentration of Salanersen in Cerebrospinal Fluid (CSF)

    Time frame: Part A: Up to Day 365 and Part B: Up to Day 1460

  14. Parts A and B: Concentration of Salanersen in Serum

    Time frame: Part A: Up to Day 365 and Part B: Up to Day 1825

07

Study locations

1 of 1 sites recruiting
  • Neurology Rare Disease Center
    Flower Mound, Texas 75028, United States
    Recruiting
    • · Contact972-999-1011
    • Diana Castro · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2029, 32 months later.

Of 18 phase 3 interventional studies under Muscular Atrophy, Spinal, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 32 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 3, 2026
StartEst.
Oct 31, 2026was Sep 2026
Primary completionEst.
Jul 27, 2029
CompletionEst.
Jul 26, 2033
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 4, 2026→Oct 31, 2026
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Start date Sep 4, 2026→Oct 31, 2026
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07444450
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Jul 27, 2029 (estimated)
Completion
Jul 26, 2033 (estimated)
Last update
Oct 15, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salanersen

Start the discussion